Navigation Links
Phase 3 data show viral cure rates achieved in a broad range of patients with genotype-1 hepatitis C taking investigational compound faldaprevir plus PegIFN/RBV
Date:11/2/2013

ymerase inhibitor that has shown the potential to eliminate interferon from HCV treatment when combined in a regimen with faldaprevir and RBV. Phase 2 trials of this interferon-free regimen have been completed and Phase 3 HCVerso® trials investigating this regimen are now underway. As part of our long-term commitment to HCV, the company is exploring other combinations of investigational HCV compounds that work in complementary ways. The recent collaboration of Boehringer Ingelheim with Presidio Pharmaceuticals, Inc. for a Phase 2a clinical study investigating an interferon- and ribavirin-free, all-oral combination is part of the company's continued commitment to discover and develop innovative options for the treatment of HCV.

STARTVerso™ and HCVerso® are registered service marks of Boehringer Ingelheim International GmbH.

The Liver Meeting® is a registered trademark of the American Association for the Study of Liver Diseases (AASLD).

Hepatitis C is a blood-borne infectious disease and a leading cause of chronic liver disease, transplant and failure that affects as many as 150 million people globally. In the United States, approximately 3.2-5.2 million people have chronic HCV infection. Since 1999 there has been a significant increase in deaths due to chronic HCV, which accounts for 10,000-12,000 deaths in the United States per year.

About Boehringer Ingelheim
Boehringer Ingelheim Pharmaceuticals, Inc., based in Ridgefield, CT, is the largest U.S. subsidiary of Boehringer Ingelheim Corporation (Ridgefield, CT) and a member of the Boehringer Ingelheim group of companies.

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 140 affiliates and more th
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
2. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
3. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
4. Retrospective Study Suggests that Stereotactic Ablative Radiotherapy (SABR) Can be a Viable Option for Treating Early-Stage Lung Cancer in Operable as well as Inoperable Patients; Phase III Randomized Trial Now Under Way
5. Ultragenyx Announces Phase 1 Results of UX001 in Hereditary Inclusion Body Myopathy (HIBM), a Rare Neuromuscular Disease
6. Lexicon Receives Funding for Phase 2 Clinical Trial of LX4211 in Type 1 Diabetes
7. Isis Initiates Phase 2 Study of ISIS-APOCIIIRx in Patients with Hypertriglyceridemia
8. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
9. Results Reported for Phase Ib Open-Label Clinical Trial for the Treatment of Depression Using External Trigeminal Nerve Stimulation (eTNS™) - The USB Port to the Brain™
10. Pearl Therapeutics Phase 2b Twice-Daily Dosing Data Suggest Morning and Evening Benefit of PT003 in Patients with COPD
11. Adamas Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA for Arimenda™
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2015)... , July 7, 2015 Noting the need ... pricing policies currently practiced by the rapidly consolidating pharmacy ... (SCPC) today praised Ohio Governor ... a new state effort to help pull back the ... "We applaud Governor Kasich for bringing badly-needed ...
(Date:7/7/2015)... Biobanks - How to Discover Trends, R&D ... ,Are you interested in the future of medical ... predictions from 2015. You stay ahead for data, benefiting ... results, opportunities and revenue forecasts. That new ... for biobanking and associated technology to improve healthcare ...
(Date:7/7/2015)... Pennsylvania , 7. Juli 2015 ... und -Technik für klinische Studien, gab heute bekannt, ... ein führendes Unternehmen bei Gewinnung und Erhalt von ... die Tochtergesellschaften MediciGlobal , Ltd. und Access ... auch einen Dienst zum Auffinden von Patienten, ...
Breaking Medicine Technology:National LTC Pharmacy Leader Praises Kasich Effort to Bring Transparency to PBM Drug Pricing 2National LTC Pharmacy Leader Praises Kasich Effort to Bring Transparency to PBM Drug Pricing 3Biobanking for Medicine: Technology, Industry and Market 2015-2025 2Biobanking for Medicine: Technology, Industry and Market 2015-2025 3Biobanking for Medicine: Technology, Industry and Market 2015-2025 4Biobanking for Medicine: Technology, Industry and Market 2015-2025 5Biobanking for Medicine: Technology, Industry and Market 2015-2025 6Biobanking for Medicine: Technology, Industry and Market 2015-2025 7Biobanking for Medicine: Technology, Industry and Market 2015-2025 8Biobanking for Medicine: Technology, Industry and Market 2015-2025 9Biobanking for Medicine: Technology, Industry and Market 2015-2025 10BioClinica übernimmt MediciGroup 2BioClinica übernimmt MediciGroup 3BioClinica übernimmt MediciGroup 4
... 2011 Nationally-acclaimed researcher and award-winning author Dr. Cynthia ... National Conference on Cancer Nursing Research that silver treated ... were supposed to prevent. After testing ... with silver coated or silver impregnated fluid pathway components, ...
... Pharmaceuticals, Inc. (Nasdaq: OPTR ) today announced the ... shares of its common stock, offered at a price to ... Optimer from this offering are expected to be $67.5 million, ... offering expenses payable by Optimer.  The offering is expected to ...
Cached Medicine Technology:Instead of Preventing Infections, Silver Coated Needleless IV Connectors May Actually Cause Them, a Nationally-Recognized Expert Tells National Conference on Cancer Nursing Research 2Optimer Pharmaceuticals, Inc. Prices Public Offering of Common Stock 2Optimer Pharmaceuticals, Inc. Prices Public Offering of Common Stock 3
(Date:7/8/2015)... ... July 08, 2015 , ... LaunchPoint, a provider of ... Gold-Level Fit-Friendly Worksite by the American Heart Association for the second year in ... and stay active through its Swellness Program, which promotes, “It’s swell to be ...
(Date:7/8/2015)... ... July 08, 2015 , ... Health & Disability ... on July 29th in Bettendorf, IA. This workshop will be presented to community-based ... members, veterans, and their families. Professionals from both civilian and military organizations are ...
(Date:7/8/2015)... ... 08, 2015 , ... Garden Retreat Spa , located in the heart ... NYC. The attractive masseuses that staff Garden Retreat Spa specialize in offering table showers, ... With plenty of parking, and a location just a few blocks from Penn Station, ...
(Date:7/7/2015)... ... 08, 2015 , ... The National Association of Professional Women (NAPW) ... the Year Circle. She is recognized with this prestigious distinction for leadership in pharmacy. ... 700,000 members and over 200 operating Local Chapters. , “I’m pleased to recognize Alyssa ...
(Date:7/7/2015)... ... July 07, 2015 , ... World Patent Marketing, a ... a medical invention that prevents IV lines from getting entangled. , "The ... be worth $133 billion by 2016," says Scott Cooper, CEO and Creative Director ...
Breaking Medicine News(10 mins):Health News:LaunchPoint Recognized with Second Consecutive American Heart Association Fit-Friendly Worksite Award 2Health News:Health & Disability Advocates to Host Military Sexual Trauma Workshop for Behavioral Health Practitioners and Victim Advocates 2Health News:Garden Retreat Spa Celebrates 8 Years Serving NYC 2Health News:National Association of Professional Women Inducts Dr. Alyssa Greedy, Pharm. D., Pharmacy Manager at Walgreens, Into its VIP Woman of the Year Circle 2Health News:New Evidence Shows Why Hospital Weekend Effect Is So Dangerous As World Patent Marketing Introduces A New Medical Invention 2Health News:New Evidence Shows Why Hospital Weekend Effect Is So Dangerous As World Patent Marketing Introduces A New Medical Invention 3Health News:New Evidence Shows Why Hospital Weekend Effect Is So Dangerous As World Patent Marketing Introduces A New Medical Invention 4Health News:New Evidence Shows Why Hospital Weekend Effect Is So Dangerous As World Patent Marketing Introduces A New Medical Invention 5
... August 2010 - The authors of a new ... strategies for reducing cocaine self-administration in animals that ... humans. Glutamate is the primary ... implicated in drug addiction. Metabotropic glutamate receptors (mGluRs) ...
... Rheumatology today announced the release of revised classification ... Against Rheumatism) for rheumatoid arthritis, which will allow ... earlier stages of the diseasebefore joint damage occursultimately ... is a chronic disease that causes pain, stiffness, ...
... , MONDAY, Aug. 9 (HealthDay News) -- Many stroke ... patients are never prescribed recommended medications in the first ... found that 25 percent of stroke patients stopped taking ... three months after their stroke. "Providers should spend ...
... national health care organizations are more likely to undergo ... of insurance, according to a study appearing in an ... Society Nephrology (JASN). The results may provide insights ... they go on dialysis. For patients whose kidneys ...
... NY, August 9, 2010Without hands-on access to doctors and hospitals, ... on telemedicine "visits" with physicians and specialists on land, a ... Telemedicine and e-Health , a peer-reviewed journal published by Mary ... free online at www.liebertpub.com/tmj Work on an ...
... After more than a decade of development at the National ... mosquito-borne dengue virus has begun human clinical testing. The vaccine ... and Infectious Diseases (NIAID) and is undergoing clinical study at ... About 2.5 billion people in more than 100 countries ...
Cached Medicine News:Health News:Drugs to treat cocaine abuse? 2Health News:New way of classifying rheumatoid arthritis aimed at identifying the disease earlier 2Health News:New way of classifying rheumatoid arthritis aimed at identifying the disease earlier 3Health News:Many Stroke Patients Stop Taking Meds, Study Shows 2Health News:Many Stroke Patients Stop Taking Meds, Study Shows 3Health News:Many Stroke Patients Stop Taking Meds, Study Shows 4Health News:Not all kidney patients treated equal: Differences in care for patients beginning on dialysis 2Health News:Not all kidney patients treated equal: Differences in care for patients beginning on dialysis 3Health News:Human clinical trial of NIH-developed dengue vaccine begins 2Health News:Human clinical trial of NIH-developed dengue vaccine begins 3
Acuvue2 is designed to be worn as a two-week daily wear lens (which means you take the lenses out each night). It can also be worn as a one-week extended wear lens (which means you can sleep in them)...
Bausch & Lomb SofLens59 contact lenses combine excellent performance, comfort and visual acuity providing daily wear for two week replacement....
The Prism Exophthalmometer provides precise measurement of patient's exophthalmos....
PLX40s, 40 Watt Sealed CO2 Laser System....
Medicine Products: